Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2011-05-03
2011-05-03
Kemmerer, Elizabeth C. (Department: 1649)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S140100, C424S278100, C604S006010
Reexamination Certificate
active
07935348
ABSTRACT:
The invention relates to a method for treating Alzheimer's disease by inducing sequestration of amyloid β into a plasma with a Aβ-mimotope peptide, and treatment with an apheresis device such that a fixed carrier can come into contact with the blood or plasma flow and includes a receptor that binds to an amyloid-β precursor-protein (APP), the APP being removed from the blood with the apheresis device.
REFERENCES:
patent: 6551266 (2003-04-01), Davis, Jr.
patent: 2007/0026029 (2007-02-01), Mattner et al.
patent: 00 72880 (2000-12-01), None
patent: 03 000719 (2003-01-01), None
patent: 03 051374 (2003-06-01), None
patent: 2004 013172 (2004-02-01), None
patent: 2004 056318 (2004-07-01), None
patent: 2004 062556 (2004-07-01), None
patent: 2005 025651 (2005-03-01), None
patent: 2006 005707 (2006-01-01), None
Janus C et al. A beta peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature, 2000; 408:979-982.
Morgan D et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 2000; 408:982-985.
Perrin RJ et al. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature, Oct. 2009; 461(7266):916-922.
Solomon B. Immunological approaches as therapy for Alzheimer's disease. Expert Opin. Biol. Ther. 2002; 2(8):907-917.
Vickers JC. A vaccine against Alzheimer's disease: developments to date. Drugs Aging. 2002; 19(7):487-494.
J. McLaurin, et al., “Therapeutically Effective Antibodies Against Amyloid-Beta Peptide Target Amyloid-Beta Residues 4-10 and Inhibit Cytotoxicity and Fibrillogenesis” Nature Medicine, vol. 8, No. 11, XP 002288573, pp. 1263-1269, 2002.
Frank L. Heppner, et al., “Current Concepts and Future Prospects for Alzheimer Disease Vaccines”, Alzheimer Disease and Associated Disorders, vol, 18, No. 1, XP 008057356, pp. 38-43, 2004.
Ulrich Reineke, et al., “Identification of Distinct Antibody Epitopes and Mimotopes From a Peptide Array of 5520 Randomly Generated Sequences”, Journal of Immunological Methods, vol. 267, No. 1, XP 004372978, pp. 37-51, 2002.
Frederique Bard, et al., “Peripherally Administered Antibodies Against Amyloid Beta-Peptide Enter the Central Nervous System and Reduce Pathology in a Mouse Model of Alzheimer Disease”, Nature Medicine, vol. 6, No. 8, pp. 916-919, 2000.
Dale Schenk, et al., “Immunization With Amyloid-Beta Attenuates Alzheimer-Disease-Like Pathology in the PDAPP Mouse”, Letters to Nature, vol. 400, pp. 173-177, 1999.
Christoph Hock, et al., “Generation of Antibodies Specific for Beta-Amyloid by Vaccination of Patients With Alzheimer Disease”, Nature Medicine, vol. 8, No. 11, pp. 1270-1275, 2002.
U.S. Appl. No. 12/752,451, filed Apr. 1, 2010, Mattner.
Mattner Frank
Schmidt Walter
Affiris Forschungs-und Entwicklungs GmbH
Ballard Kimberly A.
Kemmerer Elizabeth C.
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
LandOfFree
Combination therapy for the treatment of Alzheimer's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy for the treatment of Alzheimer's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy for the treatment of Alzheimer's disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2645745